Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New drug reduces chemotherapy-induced nausea and vomiting

15.10.2003


Two new studies now show that aprepitant – the first in a new class of drugs that interfere with the vomiting reflex – can substantially reduce chemotherapy-associated nausea and vomiting in cancer patients treated with cisplatin, a common type of chemotherapy. Results of both Journal of Clinical Oncology studies, early release articles published online October 14, formed the basis of the U.S. Food and Drug Administration’s approval of aprepitant in March 2003.



Aprepitant Combined with Standard Treatment for Nausea and Vomiting Helps Prevent These Symptoms Following Chemotherapy

The first study, led by Paul J. Hesketh, MD, at the Caritas St. Elizabeth’s Medical Center in Boston, found that adding aprepitant to the standard therapy to control nausea and vomiting could more effectively prevent these symptoms than the standard treatment alone. Nausea and vomiting were reduced both on the day that chemotherapy was given and, more importantly, in the several days that followed, when nausea and vomiting often occur.


"The nausea and vomiting that occurs 24 hours after receiving cisplatin is particularly problematic for patients, and aprepitant provided a substantial improvement," said Dr. Hesketh. "Aprepitant should change the standard of care for the treatment of chemotherapy-induced nausea and vomiting, especially for patients receiving chemotherapy drugs known to cause severe vomiting."

The international phase III study involved 520 patients with respiratory cancers, all of whom received ondansetron plus dexamethasone – the standard therapy to prevent nausea and vomiting. In addition, the patients were randomly assigned to receive oral aprepitant or a placebo. Patients kept diaries to document any nausea or vomiting that occurred on the day that chemotherapy was given and on the four days that followed, noting whether they needed additional medication to control these symptoms.

Researchers found that 26 percent of patients on the aprepitant regimen experienced nausea or vomiting, while nearly 48 percent of patients on the standard treatment experienced these side effects.

Results were particularly encouraging two to five days after the administration of chemotherapy, when standard treatments often fail. During this time period, 25 percent of patients on the aprepitant regimen reported nausea or vomiting, compared to 44 percent of those taking the standard drugs.

Aprepitant Added to Standard Therapy Protects Against Nausea and Vomiting Over Multiple Cycles of Chemotherapy

The second study, led by Ronald de Wit, MD, PhD, of the Rotterdam Cancer Institute in the Netherlands, found that the benefits of aprepitant extended over the course of multiple cycles of chemotherapy. Previous studies have shown that nausea and vomiting often become more severe over the course of several cycles of chemotherapy, and that standard therapy to control nausea and vomiting tends to become less effective as the number of chemotherapy cycles increases.

"This is a major clinical improvement in the ability to control nausea and vomiting – two of the most distressing side effects of chemotherapy," said Dr. de Wit. "The benefits experienced by patients taking aprepitant should be considered a major leap forward."

The international phase II clinical trial involved 164 cancer patients, all of whom were scheduled to receive up to six cycles of cisplatin. Recruited from 50 centers, including 21 in the United States, patients were randomly assigned to receive either oral aprepitant or a placebo, in addition to ondansetron and dexamethasone. Patients kept diaries identical to those in the previous study.

Researchers found that 64 percent of patients taking aprepitant plus standard therapy experienced no nausea or vomiting after the first cycle of cisplatin, compared to 49 percent of patients taking only the standard therapy. After six cycles of cisplatin therapy, 59 percent of patients who continued to take aprepitant along with the standard therapy reported no nausea or vomiting, compared to only 34 percent of those who received the standard therapy alone.

"This study shows that the benefits of aprepitant are not confined to the first cycle of chemotherapy and that this enhanced protection against nausea and vomiting can be sustained," said Dr. de Wit.


"The Oral NK1 Antagonist Aprepitant For the Prevention of Chemotherapy Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo Controlled Trial in Patients
Receiving High-Dose Cisplatin." Paul J. Hesketh, M.D., et al; Caritas St. Elizabeth’s Medical Center, Boston, Massachusetts.

"Addition of the Oral NK1 Antagonist Aprepitant (EMEND®) To Standard Antiemetics Provided Protection Against Nausea and Vomiting during Multiple Cycles of Cisplatin-Based Chemotherapy."
Ronald de Wit, M.D., et al; Rotterdam Cancer Institute, Rotterdam, The Netherlands.

The Journal of Clinical Oncology is the semi-monthly peer-reviewed journal of the American Society of Clinical Oncology (ASCO), the world’s leading professional society representing physicians who treat people with cancer.

Carrie Housman | EurekAlert!

More articles from Health and Medicine:

nachricht Usher syndrome: Gene therapy restores hearing and balance
25.09.2017 | Institut Pasteur

nachricht MRI contrast agent locates and distinguishes aggressive from slow-growing breast cancer
25.09.2017 | Case Western Reserve University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: LaserTAB: More efficient and precise contacts thanks to human-robot collaboration

At the productronica trade fair in Munich this November, the Fraunhofer Institute for Laser Technology ILT will be presenting Laser-Based Tape-Automated Bonding, LaserTAB for short. The experts from Aachen will be demonstrating how new battery cells and power electronics can be micro-welded more efficiently and precisely than ever before thanks to new optics and robot support.

Fraunhofer ILT from Aachen relies on a clever combination of robotics and a laser scanner with new optics as well as process monitoring, which it has developed...

Im Focus: The pyrenoid is a carbon-fixing liquid droplet

Plants and algae use the enzyme Rubisco to fix carbon dioxide, removing it from the atmosphere and converting it into biomass. Algae have figured out a way to increase the efficiency of carbon fixation. They gather most of their Rubisco into a ball-shaped microcompartment called the pyrenoid, which they flood with a high local concentration of carbon dioxide. A team of scientists at Princeton University, the Carnegie Institution for Science, Stanford University and the Max Plank Institute of Biochemistry have unravelled the mysteries of how the pyrenoid is assembled. These insights can help to engineer crops that remove more carbon dioxide from the atmosphere while producing more food.

A warming planet

Im Focus: Highly precise wiring in the Cerebral Cortex

Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.

The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Fraunhofer ISE Pushes World Record for Multicrystalline Silicon Solar Cells to 22.3 Percent

25.09.2017 | Power and Electrical Engineering

Usher syndrome: Gene therapy restores hearing and balance

25.09.2017 | Health and Medicine

An international team of physicists a coherent amplification effect in laser excited dielectrics

25.09.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>